Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 28
Filter
3.
Orv Hetil ; 154(22): 846-9, 2013 Jun 02.
Article in Hungarian | MEDLINE | ID: mdl-23708984

ABSTRACT

The first Hungarian kidney transplantation was performed by András Németh in Szeged in 1962, approximately 50 years ago. A preliminary agreement with Eurotransplant was signed in 2011, and special patient groups gained benefit from this cooperation in 2012, wnich lead to a full membership to Eurotransplant. This event inspired the authors to review the history of Hungarian kidney transplantation of the past 50 years, from the first operation to recent via the specific cornerstones of the transplant program. The donor of the first Hungarian kidney transplantation was the brother of the recipient. The operation itself was technically successful, but the lack of immunosuppression caused graft rejection, and the patient died after 79 days. His brother, the donor, is still healthy, after 50 years, and he encourages everybody to donate organs. Organized kidney transplant program started more than 10 years later, such as 1973, in Budapest. The program was supported by the Ministry of Health. New centers joined the program later, Szeged in 1979, Debrecen in 1991 and Pécs in 1993. These four transplant centers work currently in Hungary, and 6611 kidney transplantation has been performed up to the end of year 2012.


Subject(s)
Kidney Transplantation/history , Kidney Transplantation/trends , Tissue and Organ Procurement , Cadaver , History, 20th Century , History, 21st Century , Humans , Hungary , Kidney Transplantation/economics , Living Donors , Outcome and Process Assessment, Health Care , Program Development , Program Evaluation , Tissue and Organ Procurement/history , Tissue and Organ Procurement/organization & administration , Tissue and Organ Procurement/trends
4.
Orv Hetil ; 154(22): 858-62, 2013 Jun 02.
Article in Hungarian | MEDLINE | ID: mdl-23708986

ABSTRACT

The history of organ transplantation in Hungary dates back to 50 years, and the first succesful liver transplantation was performed in the United States in that time as well. The number of patients with end stage liver disease increased worldwide, and over 7000 patients die in each year due to liver disease in Hungary. The most effective treatment of end-stage liver disease is liver transplantation. The indications of liver transplantation represent a wide spectrum including viral, alcoholic or other parenchymal liver cirrhosis, but cholestatic liver disease and acute fulminant cases are also present in the daily routine. In pediatric patients biliary atresia and different forms of metabolic liver disorders represent the main indication for liver transplantation. The results of liver transplantation in Hungary are optimal with over 80% long-term survival. For better survival individual drug therapy and monitoring are introduced in liver transplant candidates.


Subject(s)
Immunosuppressive Agents/administration & dosage , Liver Transplantation , Tissue and Organ Procurement , Waiting Lists , History, 20th Century , Humans , Hungary , Immunosuppression Therapy/methods , Liver Transplantation/history , Liver Transplantation/methods , Liver Transplantation/trends , Outcome and Process Assessment, Health Care , Patient Selection , Program Development , Program Evaluation , Time Factors , Tissue and Organ Procurement/trends
5.
Transplantation ; 94(5): 492-8, 2012 Sep 15.
Article in English | MEDLINE | ID: mdl-22858806

ABSTRACT

BACKGROUND: Long-term use of corticosteroids is associated with considerable morbidity, including cardiovascular and metabolic adverse effects. METHODS: This study evaluated the long-term efficacy and safety of two steroid-free regimens compared with a triple immunosuppressive therapy in renal transplant recipients. This was a 3-year follow-up to a 6-month, open-label, randomized, multicenter study. RESULTS: Data from 3 years were available for 421 (93.3%) of 451 patients in the original intent-to-treat population (143 tacrolimus/basiliximab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/steroids [triple therapy]). In the time interval from 6 months to 3 years after transplantation, the incidence of biopsy-proven acute rejection was low and similar (Tac/Bas, 2.1%; Tac/MMF, 2.2%; triple therapy, 2.2%); Most rejection episodes occurred during the first 6 months of the study. Graft survival was high (Kaplan-Meier estimates: 92.7%, 92.5%, and 92.5%), as was patient survival (93.1%, 96.4%, and 97.0%). There were 10 graft losses (n=2, 4, and 4) and 12 patient deaths (n=5, 2, and 5). Renal function was well preserved throughout the study and similar between groups. There was a trend toward improved cardiovascular risk factors in the Tac/Bas group, including reduced total and low-density lipoprotein cholesterol and lower new-onset insulin use. There were no between-group differences in the incidence or type of adverse events. CONCLUSION: Higher rates of acute rejection early in treatment were seen with the steroid-free regimens, but this did not translate into poorer long-term outcomes, such as graft and patient survival and renal function. A trend for a more favorable cardiovascular risk profile was observed for steroid-free immunosuppression with Tac/Bas.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Graft Rejection/prevention & control , Graft Survival/drug effects , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Tacrolimus/therapeutic use , Acute Disease , Adrenal Cortex Hormones/adverse effects , Adult , Antibodies, Monoclonal/therapeutic use , Basiliximab , Biopsy , Chi-Square Distribution , Chronic Disease , Drug Therapy, Combination , Europe , Female , Follow-Up Studies , Graft Rejection/immunology , Graft Rejection/mortality , Humans , Immunosuppressive Agents/adverse effects , Kaplan-Meier Estimate , Kidney Function Tests , Kidney Transplantation/adverse effects , Kidney Transplantation/mortality , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Risk Assessment , Risk Factors , Tacrolimus/adverse effects , Time Factors , Treatment Outcome
6.
Pathol Oncol Res ; 18(3): 607-14, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22198862

ABSTRACT

The objective of the study was to examine proliferation and apoptosis associated gene expression in the whole sequence parathyroid lesions to reveal specific features of carcinoma. This study was based on surgically removed parathyroid tissues, gene expression analysis was performed both at gene and protein level. First, mRNA isolation was performed from deep-frozen tissue samples, and further apoptosis pathway-specific cDNA macroarray analysis was carried out. The results were validated with real-time PCR. Subsequently, protein expression was analyzed with immunhistochemistry on Tissue Micro Array multi-blocks derived from several paraffin-embedded samples. cDNA macroarrays revealed elevated expression of both pro-apoptotic (FAS receptor, TRAIL ligand, CASPASE8, and -4) and anti-apoptotic (cIAP1, APOLLON) genes in benign proliferative lesions compared to that in normal gland. TMA studies showed overexpression of KI67, P53, SURVIVIN and APOLLON protein and failure of expression of P27, BCL2, BAX, CHROMOGRANIN-A, SYNAPTOPHYSIN, CYCLIND1, FLIP, TRAIL, CK8, CK18, CK19 in parathyroid carcinoma was detected. These alterations in gene expression of the investigated products could be used in differentiation between beningn and malignant proliferative processes of the parathyroid gland. Authors conclude that a series of alterations in gene expression such as overexpression of APOLLON, P53, KI67 and suppression of P27, BCL2, BAX lead to uncontrolled cell proliferation, but still not leading to increased apoptotic activity in parathyroid carcinoma.


Subject(s)
Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Gene Expression Profiling , Parathyroid Glands/metabolism , Parathyroid Neoplasms/genetics , Parathyroid Neoplasms/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenoma/genetics , Adenoma/metabolism , Adenoma/pathology , Fluorescent Antibody Technique , Humans , Hyperplasia/genetics , Hyperplasia/metabolism , Hyperplasia/pathology , Immunoenzyme Techniques , Oligonucleotide Array Sequence Analysis , Parathyroid Glands/pathology , Parathyroid Neoplasms/pathology , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Tissue Array Analysis
7.
Transplant Proc ; 42(6): 2279-80, 2010.
Article in English | MEDLINE | ID: mdl-20692462

ABSTRACT

The first, long-term successful kidney transplantation happened 37 years ago in Hungary. At the same time an organized renal program was initiated followed by transplantations of other solid organs. The authors remember previous milestone operations and the preceding events. In 1982, Hungary was the first country in the Eastern block to introduce cyclosporine. After the Iron Curtain fell new circumstances and possibilities opened for the transplant community also. Young transplant surgeons were sent to Western countries returning with new experiences. In 1992 the heart transplantation program started in Budapest. The Universities of Debrecen and Pécs joined Budapest and Szeged with renal transplant programs. In 1994, a new Department was initiated at Semmelweis University with an immediate increase of 50%. The next year a liver transplantation program was launched. Pancreas transplants were performed in 1998 in Pécs, followed by Budapest. In 2003, a collaboration was initiated between Geneva and Budapest for islet transplantation and another with Vienna for lung transplantation. This article provides an overview of Hungarian transplant activities.


Subject(s)
Periodicals as Topic , Transplantation , Europe , Europe, Eastern , Humans , Hungary , Kidney Transplantation/statistics & numerical data , Politics , Societies, Medical , Universities
8.
Clin Transplant ; 24(1): E1-9, 2010.
Article in English | MEDLINE | ID: mdl-19925464

ABSTRACT

Side effects of steroid use have led to efforts to minimize their use in transplantation. Two corticosteroid-free regimens were compared with a triple immunosuppressive therapy. Data from the original intent-to-treat (ITT) population (153 tacrolimus/basiliximab [Tac/Bas], 151 tacrolimus/MMF [Tac/MMF], and 147 tacrolimus/MMF/steroids [control]) were analyzed in a 12-month follow-up. Percentage of graft survival were 92.8%, 95.4%, and 95.9% (KM estimates 89.9%, 95.3%, 95.9%), percentage of surviving patients were 98.7%, 98.0%, and 100% (KM estimates 95.9%, 92.8%, and 100%). During months 7-12, graft loss occurred in 3 Tac/Bas, 2 Tac/MMF, and zero control patients, patient deaths in 1 Tac/Bas, 2 Tac/MMF, and zero control, and biopsy-proven acute rejection episodes in 4 Tac/Bas, 3 Tac/MMF, and zero control. Mean serum creatinine at month 12 was 141.9 +/- 69.6 microM, 144.0 +/- 82.1 microM, and 134.5 +/- 71.2 microM (ns). New-onset insulin use in previously non-diabetic patients at month 12 was 1/138, 6/127, and 4/126. Patient and graft survival as well as renal function at 12 months were not different between patient groups, despite considerably higher rates of acute rejection occurring within the first six months after transplantation in both steroid-free patient groups. Tac/Bas therapy might offer benefits in terms of a trend for a more favorable cardiovascular risk profile.


Subject(s)
Glucocorticoids/administration & dosage , Immunosuppressive Agents/administration & dosage , Kidney Failure, Chronic/surgery , Kidney Transplantation , Tacrolimus/administration & dosage , Adult , Antibodies, Monoclonal/administration & dosage , Basiliximab , Drug Therapy, Combination , Female , Follow-Up Studies , Graft Rejection , Graft Survival , Humans , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/pathology , Male , Methylprednisolone/administration & dosage , Middle Aged , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/analogs & derivatives , Recombinant Fusion Proteins/administration & dosage , Survival Rate , Treatment Outcome
10.
Orv Hetil ; 149(11): 509-15, 2008 Mar 16.
Article in Hungarian | MEDLINE | ID: mdl-18343764

ABSTRACT

The time course of free radical reactions is evaluated by the authors. Within pretransplant patients as of their poorly functioning metabolism free radical overproduction may be observed, hence their antioxidant capacity decreases. When the graft is functioning well, the free radical-antioxidant balance of homeostasis is reestablished. During the early postoperative period, when symptoms (acute rejection, infection, acute tubular necrosis, cholestasis) appear, free radical reactions increase. The authors demonstrate, this is strengthened by the fact that the mediator [interleukin-6 (IL-6), C-reactive protein, serum amyloid-A], and enzyme levels that take part in the free radical processes rise. The monitoring of these parameters during the early postoperative period is a good early indicator for acute rejection and for the effect of therapy. During acute rejection just as during infection most of these parameters increased significantly compared to the healthy control. They show the activation of the immune system but they are not useful for differential diagnosis, with the exception of IL-6 which we measured in larger quantities during bacterial infection but not so in acute rejection. For the prediction of early renal graft function we used urinary enzyme levels (dipeptidyl-aminopeptidase, glutathione-S-transferase). Tissue damage is followed by enzyme increasing and antioxidant capacity depletion. With choosing of adequate tests, the perioperative redox homeostasis of the transplanted patients can be monitored and with dosing the antioxidants the uncontrolled forming of reactive oxygen metabolites can also be decreased and checked.


Subject(s)
Free Radicals/metabolism , Graft Rejection/diagnosis , Kidney Transplantation , Liver Transplantation , Oxidation-Reduction , Acute Disease , Adult , Antioxidants/administration & dosage , Biomarkers/blood , Biomarkers/urine , C-Reactive Protein/metabolism , Case-Control Studies , Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/urine , Female , Glutathione Transferase/urine , Graft Rejection/blood , Graft Rejection/urine , Humans , Interleukin-6/blood , Luminescent Measurements , Male , Middle Aged , Neopterin/blood , Serum Amyloid A Protein/metabolism
11.
Pathol Oncol Res ; 13(1): 63-9, 2007.
Article in English | MEDLINE | ID: mdl-17387391

ABSTRACT

This study provides an analysis of incidence and characteristics of malignant tumors of 2535 patients who underwent renal transplantation between 1973 and 2007 at the Transplantation Center in Budapest. One hundred ninety-three malignant diseases were found in 188 patients (7.6%). The incidence of thyroid-, renal- hepatic-, skin- and gastric cancers as well as of Kaposi sarcoma and lymphomas increased in our transplant patient cohort compared to the figures of the general population based on the data of our Cancer Registry. On the other hand, colorectal-, oralprostate and lung cancers were underrepresented in our patient cohort. The mean time of diagnosis of malignancies following kidney transplantation was 58.5+/-44.8 months. One fifth of the tumors were detected within the first year. Patients with malignancies were distributed into four groups based on the immunosuppressive regimen: group I (8.5%), azathioprine + prednisone; group II (59.0%), cyclosporine + prednisone; group III (26.6%), cyclosporine + mycophenolate mofetil + prednisone; group IV (5.9%), tacrolimus + mycophenolate mofetil + prednisone. The mean age of patients was 47.3, 53.5, 55.5 and 58.1 years in group I, II, III and IV, respectively. Oncologic and immunosuppressive therapy was decided individually. Immunosuppression was switched to rapamycin-containing regimens in 63 cases. We lost 92 patients (48.9%) with a mean survival time of 25.8+/-39.4 months. Cumulative 1- and 5-year survivals were 69.5% and 52%, respectively. The increasing number of cancers seen early after transplantation and the increased risk of developing a cancer due to the older age of recipients draw attention to the importance of regular oncologic screening in patients on the waiting list and after transplantation.


Subject(s)
Immunosuppressive Agents/adverse effects , Kidney Transplantation , Neoplasms/epidemiology , Adult , Aging , Female , Humans , Hungary/epidemiology , Incidence , Male , Middle Aged , Neoplasms/etiology , Neoplasms/mortality , Retrospective Studies , Risk Factors , Survival Rate , Time Factors
12.
Magy Onkol ; 50(2): 137-40, 2006.
Article in Hungarian | MEDLINE | ID: mdl-16888677

ABSTRACT

The aim of this study was to investigate the changes in expression pattern of the most important genes connected with apoptosis in proliferative apoptotic lesions (hyperplasia, adenoma), applying cDNA microarray technique, in order to promote the possible diagnostic or therapeutic utilisation of any difference in gene expression compared to the healthy (normal) parathyroid gland. Samples were taken from surgically removed 2 hyperplasias, 2 adenomas and 2 normal parathyroid glands. The Apoptosis Gene Array (Superarray) was used. This contains 112 genes, in tetraspot arrangement. The probes measured 250-600 base pairs. Streptavidin was bound to the array. CDP Star TM chemiluminescent substrate was used for detection. The samples deriving from hyperplasia or adenoma were compared to samples from normal parathyroid glands. The following genes were overexpressed in both hyperplasia and adenoma: CHEK1, ATM, BCL-XL, FAS, TNF, cIAP1, TRAIL, FADD, CASP 4,5,6,8, CD120b, CD137, LTA, TANK, TARF2, CAD, LIGHTR, DR3LG. CASP1,10, BFAR, BOD, BCL2L2, TRANCE were underexpressed in both hyperplasia and adenoma. Genes overexpressed only in hyperplasia were: MDM2, MCL1, BCL2A1, BLK, RIPK2, CD40LG, TRAF5, HUS1, BNIP3. Underexpressed only in hyperplasia: BOK, CIDEA, TRAF1, TRIP. Overexpressed only in adenoma: APOLLON, RIPK1, LTB, LTBR, CASP2,13, cIAP2, CIDEB. Underexpressed only in adenoma: TRAF4 and FASLG. Overexpresion or underexpression meant 1.5-fold difference from normal average values. As a result of this study, both pro-apoptotic and antiapoptotic genes were identified in hyperplasia and adenoma of the parathyroid gland. It seems that increased proliferation is connected also with increased apoptotic activity, but tumor cell candidates are able to survive, by activation of signal pathways resulting in overexpresion of anti-apoptotic genes.


Subject(s)
Adenoma/genetics , Apoptosis/genetics , Gene Expression Regulation, Neoplastic , Gene Expression , Parathyroid Glands/metabolism , Parathyroid Neoplasms/genetics , Cell Proliferation , DNA, Complementary , Down-Regulation , Gene Expression Profiling , Humans , Hyperplasia/genetics , Indicators and Reagents , Luminescence , Oligonucleotide Array Sequence Analysis , Parathyroid Glands/pathology , Streptavidin , Up-Regulation
13.
Orv Hetil ; 147(2): 51-9, 2006 Jan 15.
Article in Hungarian | MEDLINE | ID: mdl-16509213

ABSTRACT

INTRODUCTION: Primary aldosteronism is the most common form of mineralocorticoid hypertension. The disease has been described by Jerome W. Conn in 1955; since that time there has been a great progress in the knowledge concerning the prevalence, diagnostics and treatment of the disease. AIMS: The authors retrospectively analyzed the efficacy of diagnostic procedures and the outcome of treatment by the analysis of data of 187 patients with primary aldosteronism examined between 1958 and 2004 at the 2nd Department of Medicine of Semmelweis University. METHODS: The efficacy of different methods used for the diagnosis, the frequency of the different subtypes of primary aldosteronism, as well as the surgical outcomes in patients with surgically treated subtypes of primary aldosteronism were studied. RESULTS: Aldosterone-producing adenoma was detected in more than two thirds of patients (n = 135), whereas idiopathic hyperaldosteronism was found in 46 patients. Other subtypes of primary hyperaldosteronism occurred less frequently (unilateral primary adrenocortical hyperplasia in 5 patients and adrenocortical carcinoma in one patient). For the diagnosis of familial hyperaldosteronism type I, molecular biological studies of the aldosterone-synthase/11beta-hydroxylase gene chimera were carried out in 30 patients but none of them showed the presence of the chimeric gene. When comparing the clinical parameters of patients with aldosterone-producing adenoma and idiopathic hyperaldosteronism, no significant differences were found in the time period between the diagnosis of hypertension and the diagnosis of primary aldosteronism, or in the systolic and diastolic blood pressure values. The mean of the lowest documented serum potassium concentration was slightly lower in patients with aldosterone-producing adenoma (2.8 +/- 0.1 mmol/l) compared to those with idiopathic hyperaldosteronism (3.1 +/- 0.2 mmol/l), but the difference was not significant. Normokalemic primary hyperaldosteronism was found in 7 cases. The ratio of plasma aldosterone concentration (ng/dl) to plasma renin activity (ng/ml/h) was above 20 in all patients with aldosterone-producing adenoma and in all but 5 cases with idiopathic hyperaldosteronism. To confirm the diagnosis and to differentiate the subtypes of primary aldosteronism, the postural test combined with furosemide administration was performed in the majority of patients. When cases showing an elevation of plasma cortisol level during the test were excluded, this test differentiated patients with aldosterone-producing adenoma from those with idiopathic hyperaldosteronism with a sensitivity of 69% and a specificity of 92%. In cases of adrenocortical adenomas not or not clearly detectable by radiological imaging techniques, as well as in cases with bilateral adrenocortical adenomas, selective adrenal vein sampling was performed (n = 55). All but 4 patients with aldosterone-producing adenoma underwent adrenalectomy. Histology and postoperative hormone results confirmed the preoperative diagnosis in all operated patients. After surgery serum potassium concentration returned to normal in all patients showing low serum potassium levels before surgery. Also, the moderate to severe preoperative hypertension disappeared or improved after surgery. CONCLUSIONS: These observations are in contrast with the results of international studies which showed a high frequency of normokalemic primary aldosteronism and a more frequent occurrence of idiopathic hyperaldosteronism well treatable with aldosterone-antagonists. Therefore, it can be presumed that a significant number of primary aldosteronism cases that are not accompanied with severe hypokalemia remain undetected in Hungary.


Subject(s)
Adenoma/surgery , Adrenal Cortex Neoplasms/surgery , Aldosterone/metabolism , Hyperaldosteronism/diagnosis , Hyperaldosteronism/therapy , Mineralocorticoid Receptor Antagonists/therapeutic use , Adenoma/metabolism , Adrenal Cortex Neoplasms/metabolism , Adrenalectomy , Adult , Aged , Cytochrome P-450 CYP11B2/genetics , Female , Humans , Hungary/epidemiology , Hyperaldosteronism/blood , Hyperaldosteronism/complications , Hyperaldosteronism/epidemiology , Hyperaldosteronism/genetics , Hyperkalemia/etiology , Hypertension/etiology , Male , Middle Aged , Mutant Chimeric Proteins/genetics , Retrospective Studies , Steroid 11-beta-Hydroxylase/genetics
14.
Transplantation ; 80(12): 1734-41, 2005 Dec 27.
Article in English | MEDLINE | ID: mdl-16378069

ABSTRACT

BACKGROUND: The side effects associated with corticosteroids have led to efforts to minimize their use in renal transplant patients. In this study we compared two corticosteroid-free tacrolimus-based regimens with a standard triple therapy. METHODS: This was a 6-month, phase III, open-label, parallel-group, multicenter study. The total analysis set comprised 451 patients, randomized (1:1:1) to receive tacrolimus (Tac) monotherapy following basiliximab (Bas) administration (n=153), Tac/mycophenolate mofetil (MMF) (n=151), or, Tac/MMF/corticosteroids triple therapy as a control (n=147). RESULTS: The study was completed by 91.2% (triple therapy), 94.7% (Tac/MMF), and 82.4% (Bas/Tac) of patients. Patient baseline characteristics were similar in all groups. The incidences of biopsy-proven acute rejection were 8.2% (triple therapy), 30.5% (Tac/MMF), and 26.1% (Bas/Tac), p<0.001 (multiple test for comparison with triple therapy); Bas/Tac vs. Tac/MMF, p=ns. The incidences of corticosteroid-resistant acute rejection were 2.0%, 4.0%, and 5.2%, p=ns. Graft survival (95.9%, 96.7%, and 94.7%, p=ns) and patient survival (100%, 99.3%, and 99.3%, p=ns) were similar in all groups. Median serum creatinine at month 6 was 123.0 micromol/L (triple therapy), 134.7 micromol/L (Tac/MMF) and 135.8 micromol/L (Bas/Tac). The overall safety profiles were similar; differences (p<0.05) were reported for anaemia (24.5% vs. 12.6% vs. 14.5%), diarrhoea (12.9% vs. 17.9% vs. 5.9%), and leukopenia (7.5% vs. 18.5% vs. 5.9%) for the triple therapy, Tac/MMF, and Bas/Tac group, respectively. The incidences of new-onset diabetes mellitus were 4.6%, 7.1%, and 1.4%, respectively. CONCLUSION: Corticosteroid-free immunosuppression was feasible with the Bas/Tac and the Tac/MMF regimens. Both corticosteroid-free regimens were equally effective in preventing acute rejection, with the Bas/Tac therapy offering some safety benefits.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Kidney Transplantation/immunology , Recombinant Fusion Proteins/therapeutic use , Tacrolimus/administration & dosage , Tacrolimus/therapeutic use , Adrenal Cortex Hormones , Adult , Aged , Basiliximab , Drug Administration Schedule , Drug Therapy, Combination , Humans , Immunosuppressive Agents/therapeutic use , Kidney Failure, Chronic/surgery , Kidney Transplantation/mortality , Middle Aged , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Survival Analysis , Treatment Failure , Treatment Outcome
15.
Magy Seb ; 58(3): 155-61, 2005 Jun.
Article in Hungarian | MEDLINE | ID: mdl-16167468

ABSTRACT

The authors evaluate the results of the technical variants of liver transplantion in the first 10 years. They present the technique of conventional and piggyback liver transplantation. Their aim is to compare the outcome of the two surgical implantation techniques. Using the piggyback technique, the need for intraoperative blood transfusion was less (10U) compared to conventional transplantion (15U). Vascular complication rate was lower with conventional, compared to piggy back technique. Hepatic artery thrombosis rate was higher (14% vs. 5%) while venous outflow occlusion rate was lower (0% vs. 8%) in conventional technique compared to piggyback. Postoperative kidney failure was more frequent after conventional and crossclamp technique (45%). The 1, 3, and 5 year cumulative patient survival rates were 62%, 55% and 52% in the conventional group, and 79%, 71% is 63% after piggyback. The 1, 3 and 5 years graft survival were 60%, 53% and 50% after conventional and 74%, 66% and 60% after piggyback implantation. The piggyback technique became routine standard procedure in Hungary, with lower transfusion need, less kidney failure and very good results.


Subject(s)
Liver Transplantation/adverse effects , Liver Transplantation/methods , Adult , Blood Transfusion/statistics & numerical data , Female , Graft Survival , Humans , Hungary/epidemiology , Intraoperative Care/methods , Liver Transplantation/mortality , Male , Middle Aged , Renal Insufficiency/epidemiology , Renal Insufficiency/etiology , Retrospective Studies , Survival Rate , Treatment Outcome
16.
Orv Hetil ; 146(30): 1567-74, 2005 Jul 24.
Article in Hungarian | MEDLINE | ID: mdl-16136733

ABSTRACT

UNLABELLED: Clinical factors in association with the complications and the outcome of liver transplantation. The Hungarian experience. Demography, morbidity, perioperative characteristics and mortality. INTRODUCTION: The authors summarize the demographic, morbidity and mortality characteristics of the Hungarian Liver Transplant Program. They evaluate the changes and development, that has taken place with regard to indications, recipient population and characteristics, operation technique, and peroperative patient management. METHOD: In order to present the development, data are compared between two time periods (before and after 1999). Categorical variables are evaluated by chi-square test, continuous ones are with Levene Test (for homogeneity of means), Student T test and Mann-Whitney U-test. Cumulative survivals are computed with Kaplan-Meyer log rank analysis. Variables showed statistical significance on survival bz univariate analysis were then put into multivariate Cox-regression analysis. ROC analysis was performed to set the cut off point of certain continuous parameters in relation to survival. RESULTS: The results are summarized on Tables and statistical Figures. Regarding patients mortality in the beginning the main factors with impact were respectively technical ones like arterial thrombosis, while in the last 4 years perioperative fluid management and transfusion policy became important. Both sepsis and postoperative renal insufficiency remained key factors for mortality, however their incidence diminished dramatically. DISCUSSION: The overall outcome of the retrospective analysis is, that the program has been developed to European standards with respect to its volume, technical capabilities and results.


Subject(s)
Liver Transplantation , Analysis of Variance , Biliary Tract Diseases/etiology , Blood Loss, Surgical/prevention & control , Female , Graft Rejection/prevention & control , Hepatic Artery , Hepatorenal Syndrome/complications , Humans , Hungary/epidemiology , Immunosuppressive Agents/administration & dosage , Liver Transplantation/adverse effects , Liver Transplantation/methods , Liver Transplantation/mortality , Male , Patient Selection , Postoperative Complications/epidemiology , Postoperative Complications/etiology , Proportional Hazards Models , ROC Curve , Renal Insufficiency/etiology , Retrospective Studies , Risk Factors , Sepsis/etiology , Statistics, Nonparametric , Survival Analysis , Thrombosis/etiology , Treatment Outcome
17.
Orv Hetil ; 146(27): 1423-32, 2005 Jul 03.
Article in Hungarian | MEDLINE | ID: mdl-16089102

ABSTRACT

INTRODUCTIONS: The authors summarize the demographic, morbidity and mortality characteristics of the Hungarian Liver Transplant Program. AIMS: They evaluate the changes and development, that has taken place with regard to indications, recipient population and characteristics, operation technique, and peroperative patient management. METHOD: In order to present the development, data are compared between two time periods (before and after 1999). The results are summarized on Tables and statistical Figures. Categorical variables are evaluated by chi2-test, continuous ones are with Levene Test (for homogeneity of means), Student T test and Mann-Whitney U-test. Cumulative survivals are computed with Kaplan-Meier log rank analysis. RESULTS: 194 primary liver transplantation have been performed. The hepatitis C was the leading indication from the beginning. Ten (10) liver transplantation have been performed in 1995, while 44 in 2004. The mortality within the first 2 months decreased from 24% to 5%. The 1, 3 and 5 year cumulative patient survival increased from 55%, 45% es 39% (1995-1997), to 72%, 64% es 61% (1998-2000). Recently this is 78%, 77% es 77%. CONCLUSIONS: Between 1995-1997 conventional liver transplantation became standard, while piggy back turned to be popular from 1998. From 1999 the HCV-PCR monitoring, the combined antiviral treatment, the UW perfusion of the donors took place. From 2003 we introduced the tailored immunosuppression, the steroid-free protocol for viral diseases. Total infused volume was decreased together with the amount of transfusion. The retrograde graft reperfusion (from the caval side) was introduced in 2004 together with the split technique in the liver transplantation and the rebirth of the pediatric program. The overall outcome of the retrospective analysis is, that the program has been developed to European standards with respect to its volume, technical capabilities and results.


Subject(s)
Liver Transplantation/mortality , Liver Transplantation/statistics & numerical data , Adolescent , Adult , Antibiotic Prophylaxis/methods , Child , Child, Preschool , Female , Graft Rejection/prevention & control , Humans , Hungary/epidemiology , Immunosuppression Therapy/methods , Liver Diseases/surgery , Male , Middle Aged , Program Evaluation , Retrospective Studies , Survival Rate , Transplantation Conditioning
18.
Transpl Int ; 18(2): 157-62, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15691267

ABSTRACT

The 6 month prospective, randomized study compared the steroid-sparing potential of two tacrolimus-based regimens after renal transplantation. A total of 489 patients were randomized (1:1) to receive tacrolimus/mycophenolate mofetil (MMF)/steroids (n = 243; group Tac/MMF/S) or tacrolimus/azathioprine/steroids (n = 246; group Tac/Aza/S). At 3 months, steroids were tapered off in 267 (54.6%) patients free from steroid-resistant acute rejection and with serum creatinine concentrations <160 micromol/l. The incidence of biopsy-confirmed acute rejection at month 3 was lower in group Tac/MMF/S compared with group Tac/Aza/S (18.1% vs. 26.0%,P = 0.035). Moreover, more patients in the Tac/MMF/S group met the criteria for steroid withdrawal than in the Tac/Aza/S group (60.5% vs. 48.8%; P < 0.01). The incidence of acute rejection during months 4-6 was low in all groups, both for patients on steroid-free dual therapy (Tac/MMF: 2.7%, Tac/Aza: 0.8%) and for patients who continued steroid maintenance therapy (Tac/MMF/S: 3.5%, Tac/Aza/S: 7.1%). Moreover, kidney function was well preserved in steroid-free patients with month 6 median serum creatinine levels of 119.5 micromol/l (Tac/MMF), and 115.1 micromol/l (Tac/Aza). For patients who continued to receive steroids, month 6 median creatinine levels were 130.5 micromol/l (Tac/MMF/S) and 132.8 micromol/l (Tac/Aza/S). The criteria for the selection of patients to discontinue steroids were adequate. Both tacrolimus-based regimens allowed the safe discontinuation of steroids in low-risk patients at month 3. The Tac/MMF combination was superior in the prevention of acute rejections and more patients met the chosen criteria for steroid withdrawal.


Subject(s)
Immunosuppressive Agents/administration & dosage , Kidney Transplantation , Mycophenolic Acid/analogs & derivatives , Steroids/administration & dosage , Tacrolimus/administration & dosage , Adolescent , Adult , Aged , Azathioprine/administration & dosage , Creatinine/blood , Female , Graft Rejection/drug therapy , Graft Rejection/prevention & control , Humans , Kidney Transplantation/adverse effects , Kidney Transplantation/pathology , Kidney Transplantation/physiology , Male , Methylprednisolone/administration & dosage , Middle Aged , Mycophenolic Acid/administration & dosage , Prednisolone/administration & dosage , Prospective Studies
19.
Orv Hetil ; 145(20): 1053-9, 2004 May 16.
Article in Hungarian | MEDLINE | ID: mdl-15202327

ABSTRACT

An up-to-date synthesis of pancreatic islet allotransplantation is included in this summary, with emphasis on new developments and clinical results of the field. Rationale for islet transplantation in type 1 diabetes mellitus, current patient selection criteria, clinical data, technical aspects of organ procurement, islet isolation and transplantation are highlighted. The current challenges are also presented and analysed. Significant advances in clinical islet transplantation have been achieved recently. New immunosuppressive strategies were introduced, there were considerable changes in the patient selection criteria. International collaborations were established in order to standardize islet isolation and transplantation procedures. The spectacular results, recently reported by the Edmonton-group, represent a major breakthrough of the field and the outcomes are comparable with the results of whole pancreas transplantation. Islet transplantation became one of the most promising fields of tolerance induction research. Although still considered experimental, within the frameworks of expanding international collaborations, pancreatic islet allotransplantation gains more and more recognition in the clinical practice. These elements give hope that diabetes might be in the near future treated by islet cell transplantation.


Subject(s)
Islets of Langerhans/surgery , Pancreas Transplantation , Animals , Graft Rejection , History, 20th Century , Humans , Immunosuppression Therapy , Pancreas Transplantation/history , Pancreas Transplantation/methods , Patient Selection , Transplantation, Homologous , Treatment Outcome
20.
Pathol Oncol Res ; 10(2): 98-103, 2004.
Article in English | MEDLINE | ID: mdl-15188026

ABSTRACT

Altogether 107 patients were operated on at the Department of Transplantation and Surgery of Semmelweis University in the past four years, for clinical symptoms of hyperparathyroidism. Clinical and laboratory data of the patients supported the diagnosis of primary or secondary hyperparathyroidism. Chronically impaired renal function was found in 52 cases. The removed parathyroid glands showed hyperplasia in 54, adenoma in 50 and carcinoma in 3 cases. The majority of parathyroid lesions in primary hyperparathyroidism were adenomas (41 cases) and in secondary hyperparathyroidism were hyperplasias (43 cases). The ratio of oxyphil to chief cells as well as occasional mitotic and apoptotic figures were determined. The oxyphil component was present in both hyperplastic and tumorous lesions. Apoptosis and mitosis were rarely seen in hyperplasias and adenomas (under 2%), whereas in carcinomas 3% of the tumor cells were apoptotic and 4% showed mitosis. Cytoplasmic p53 positivity could be observed in 3 of the adenomas and in 2 of the hyperplasias. The carcinomas, four adenomas and 3 hyperplasias showed nuclear p53 positivity. Bcl-2 and Bax were detected in the cytoplasm of the tumor cells in the majority of adenomas and in the cells of hyperplasias. Oxyphil cells were more frequently positive than chief cells or clear cells. Colocalization of Bcl-2 and Bax was found randomly in all types of lesions. The very low incidence of carcinoma, the low mitotic and apoptotic ratio in adenomas and hyperplasias suggest a potent antiproliferative defense mechanism in the parathyroid cell population. This may also be reflected in the cytoplasmic colocalization of various gene products which regulate cell death and cell proliferation. No significant differences in the p53, Bcl-2 and Bax spectrum were found between the primary and secondary (i.e. renal failure) parathyroid alterations.


Subject(s)
Apoptosis , Hyperparathyroidism/metabolism , Parathyroid Glands/metabolism , Parathyroid Neoplasms/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Tumor Suppressor Protein p53/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adenoma/metabolism , Adenoma/pathology , Cell Proliferation , Cytoplasm , Female , Humans , Hyperparathyroidism/pathology , Hyperplasia/metabolism , Hyperplasia/pathology , Male , Middle Aged , Mitosis , Oxyphil Cells/metabolism , Oxyphil Cells/pathology , Parathyroid Glands/pathology , Parathyroid Neoplasms/pathology , bcl-2-Associated X Protein
SELECTION OF CITATIONS
SEARCH DETAIL
...